TABLE 1:
Pt/Age, y/Sex | IV tPA | Initial NIHSS score | Time to First MR Study, h:min | Initial DWI Volume, cm3 | Enhancement Pattern | Contrast Agent Dose† | Follow-Up Studies* | Hemorrhage |
---|---|---|---|---|---|---|---|---|
1/57/F | Yes | 14 | 5:00 | 44.73 | Vascular | 1× | MR3, CT | AH |
2/71/M | Yes | 12 | 4:00 | 62.73 | Parenchymal and vascular | 1× | CT | SH |
3/66/M | Yes | 19 | 3:30 | 117.58 | Vascular | 1× | MR3, CT | None |
4/72/F | Yes | 16 | 4:00 | 17.65 | Vascular | 1× | MR3 | None |
5/56/M | Yes | 10 | 3:00 | 18.59 | Parenchymal and vascular | 1× | MR3, CT | AH |
6/68/M | Yes | 15 | 5:30 | 28.09 | Parenchymal and vascular | 1× | MR3, CT | SH |
7/63/F | No | 14 | 6:00 | 33.66 | Vascular | 2× | MR3, MR7 | AH |
8/70/M | No | 16 | 6:30 | 58.07 | Vascular | 2× | MR3, MR7 | None |
9/67/F | No | 7 | 5:00 | 16.59 | Vascular | 2× | MR3, MR7 | None |
10/67/F | No | 5 | 6:00 | 34.6 | Vascular | 2× | MR3, MR7 | None |
11/84/F | No | 13 | 5:00 | 8.47 | Vascular | 2× | MR3, MR7 | None |
12/75/M | No | 5 | 6:30 | 10.79 | Vascular | 2× | MR3, MR7 | None |
13/74/F | No | 15 | 3:30 | 13.88 | Vascular | 2× | MR3, MR7, CT | None |
14/52/M | No | 10 | 5:00 | 35.6 | Vascular | 2× | MR3 | None |
15/77/M | No | 16 | 2:00 | 12.92 | Vascular | 2× | MR3, MR7, CT | None |
16/81/F | No | 17 | 3:00 | 84.81 | Vascular | 1× | MR3, MR7 | None |
17/78/F | No | 5 | 5:00 | 16.52 | Vascular | 2× | MR3, MR7 | None |
18/55/M | No | 21 | 6:00 | 65.07 | Vascular | 2× | MR3, MR7 | AH |
19/77/M | No | 7 | 6:30 | 2.3 | Vascular | 2× | MR3, MR7 | AH |
20/46/F | No | 14 | 6:30 | 12.41 | Vascular | 2× | MR3, MR7 | None |
21/57/M | No | 16 | 7:00 | 72.65 | Vascular | 2× | MR3, MR7 | AH |
22/78/M | No | 20 | 3:30 | 90.43 | Vascular | 2× | MR3, MR7 | AH |
MR3 indicates MR imaging at day 3; MR7, MR imaging at day 7.
Gadopentetate dimeglumine dose, 0.1 mmol/kg (= 1×) or 0.2 mmol/kg (= 2×).